DPP4

DRUG4 trials

Sponsors

First Affiliated Hospital Xi'an Jiaotong University, Kaiser Permanente, Brigham and Women's Hospital, Vrije Universiteit Medisch Centrum

Conditions

Adult-onset diabetes Type 2 Diabetes MellitusCardiovascular DiseasesDiabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 4

A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on r

Active, not recruitingNL-OMON48622

Vrije Universiteit Medisch CentrumAdult-onset diabetes Type 2 Diabetes Mellitus

Start: 2017-12-12Target: 66Updated: 2024-02-28

Unknown Phase

Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

First Affiliated Hospital Xi'an Jiaotong UniversityType 2 Diabetes Mellitus

Start: 2017-07-01End: 2020-01-01Target: 135Updated: 2017-06-08

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

CompletedNCT05073692

Kaiser PermanenteCardiovascular Diseases, Type 2 Diabetes Mellitus

Start: 2021-07-01End: 2025-03-12Updated: 2025-11-21

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Brigham and Women's HospitalDiabetes Mellitus, Type 2

Start: 2021-07-01End: 2024-06-30Target: 550000Updated: 2023-06-22

Related Papers

Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia

Experimental and Therapeutic Medicine2021-01-156 citations